Becton, Dickinson and Company Insider Trading

BDX

Last 12 months

Insiders sold $2.79M and bought nothing on the open market.

77% of the selling was scheduled in advance under 10b5-1 plans. EVP and President, EMEA Roland Goette sold 441K on Aug 11, 13% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$2.79M

0 buys · 21 sales

Under a 10b5-1 plan

77%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Aug 2025

Aug 11, 2025

Get an email when BDX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 26	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	76	$198.13	15K	0.4%	Form 4
Sep 28	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	76	$183.70	14K	0.4%	Form 4
Aug 26	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	165	$188.49	31K	0.8%	Form 4
Aug 13	Thomas E Polen Jr Chairman, CEO and President	Sold10b5-1 plan	4,152	$185.00	768K	3.6%	Form 4
Aug 11	Roland Goette EVP and President, EMEA	SoldNo plan	2,438	$180.84	441K	13%	Form 4
Jul 27	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	75	$157.13	12K	0.4%	Form 4
Jun 26	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	75	$152.80	11K	0.4%	Form 4
Jun 24	Michael David Garrison EVP & Pres Med.Essntl&BioPharm	Sold10b5-1 plan	1,100	$145.66	160K	7.7%	Form 4
Jun 10	Michael David Garrison EVP & Pres Med.Essntl&BioPharm	Sold10b5-1 plan	1,100	$151.48	167K	7.2%	Form 4
Jun 1	Thomas E Polen Jr Chairman, CEO and President	Sold10b5-1 plan	2,764	$146.35	405K	2.4%	Form 4
May 26	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	75	$147.35	11K	0.4%	Form 4
Apr 27	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	74	$151.94	11K	0.3%	Form 4
Mar 26	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	75	$156.83	12K	0.4%	Form 4
Feb 26	Michael Feld EVP, Chief Revenue Officer	Sold10b5-1 plan	75	$181.84	14K	0.4%	Form 4
Feb 18	Bertram L Scott Director	SoldNo plan	953	$182.61	174K	2.5%	Form 4
Jan 26	Michael Feld EVP, CRO & Pres. Life Sciences	Sold10b5-1 plan	75	$202.73	15K	0.5%	Form 4
Jan 15	Michael David Garrison EVP & Pres Med.Essntl&BioPharm	Sold10b5-1 plan 2 parts	1,610	$207.46 average	334K	12%	Form 4
Dec 26, 2025	Michael Feld EVP, CRO & Pres. Life Sciences	Sold10b5-1 plan	74	$196.08	15K	0.4%	Form 4
Dec 17, 2025	Michael David Garrison EVP & Pres Med.Essntl&BioPharm	Sold10b5-1 plan	629	$196.03	123K	4.6%	Form 4
Dec 1, 2025	Michael Feld EVP, CRO & Pres. Life Sciences	Sold10b5-1 plan	75	$193.36	15K	0.5%	Form 4
Nov 7, 2025	Bertram L Scott Director	SoldNo plan	217	$176.58	38K	0.6%	Form 4
Oct 27, 2025	Michael Feld EVP & President, Life Sciences	Sold10b5-1 plan	57	$186.01	11K	0.7%	Form 4
Sep 26, 2025	Michael Feld EVP & President, Life Sciences	Sold10b5-1 plan	58	$181.03	10K	0.7%	Form 4
Sep 10, 2025	Claire Fraser Director	SoldNo plan	917	$187.50	172K	4.0%	Form 4
Aug 22, 2025	Michael Feld EVP & President, Life Sciences	Sold10b5-1 plan	57	$197.99	11K	0.7%	Form 4
Aug 11, 2025	Gregory Hayes Director	Bought	5,250	$191.57	$1.01M	660%	Form 4
Aug 8, 2025	Claire Fraser Director	SoldNo plan	863	$192.30	166K	3.6%	Form 4
Jul 18, 2025	Michael David Garrison EVP & President, Medical	Sold10b5-1 plan 2 parts	1,185	$180.29 average	214K	20%	Form 4
Jun 2, 2025	David Shan EVP and Chief ISC Officer	Sold10b5-1 plan	1,166	$171.19	200K	20%	Form 4
Apr 9, 2025	Michael David Garrison EVP & President, Medical	Sold10b5-1 plan	479	$197.28	94K	8.9%	Form 4
Mar 18, 2025	Richard Byrd EVP & President Interventional	Sold10b5-1 plan	459	$230.00	106K	6.2%	Form 4
Mar 12, 2025	Richard Byrd EVP & President Interventional	Sold10b5-1 plan	1,940	$224.91	436K	21%	Form 4
Feb 12, 2025	Bertram L Scott Director	SoldNo plan	700	$227.99	160K	1.9%	Form 4
Feb 10, 2025	Jeffrey William Henderson Director	Bought	1,500	$233.62	350K	23%	Form 4
Jan 21, 2025	David Shan EVP and Chief ISC Officer	Sold10b5-1 plan	500	$240.00	120K	8.0%	Form 4
Jan 21, 2025	Shana Carol Neal EVP and Chief People Officer	Sold10b5-1 plan	787	$240.00	189K	4.9%	Form 4
Jan 17, 2025	Michael David Garrison EVP & President, Medical	Sold10b5-1 plan	597	$236.51	141K	9.7%	Form 4
Jan 7, 2025	Shana Carol Neal EVP and Chief People Officer	Sold10b5-1 plan	788	$235.00	185K	4.6%	Form 4
Dec 19, 2024	Michael David Garrison EVP & President, Medical	Sold10b5-1 plan	2,838	$223.33	634K	32%	Form 4
Dec 6, 2024 – Dec 9, 2024	Roland Goette EVP and President, EMEA	Sold10b5-1 plan 2 parts	5,121	$220.76 average	$1.13M	25%	Form 4

Oct 2610b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 76 at $198.13
15K
0.4% of stake
Sep 2810b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 76 at $183.70
14K
0.4% of stake
Aug 2610b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 165 at $188.49
31K
0.8% of stake
Aug 1310b5-1 plan
Thomas E Polen Jr
Chairman, CEO and President · sold 4,152 at $185.00
768K
3.6% of stake
Aug 11No plan
Roland Goette
EVP and President, EMEA · sold 2,438 at $180.84
441K
13% of stake
Jul 2710b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 75 at $157.13
12K
0.4% of stake
Jun 2610b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 75 at $152.80
11K
0.4% of stake
Jun 2410b5-1 plan
Michael David Garrison
EVP & Pres Med.Essntl&BioPharm · sold 1,100 at $145.66
160K
7.7% of stake
Jun 1010b5-1 plan
Michael David Garrison
EVP & Pres Med.Essntl&BioPharm · sold 1,100 at $151.48
167K
7.2% of stake
Jun 110b5-1 plan
Thomas E Polen Jr
Chairman, CEO and President · sold 2,764 at $146.35
405K
2.4% of stake
May 2610b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 75 at $147.35
11K
0.4% of stake
Apr 2710b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 74 at $151.94
11K
0.3% of stake
Mar 2610b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 75 at $156.83
12K
0.4% of stake
Feb 2610b5-1 plan
Michael Feld
EVP, Chief Revenue Officer · sold 75 at $181.84
14K
0.4% of stake
Feb 18No plan
Bertram L Scott
Director · sold 953 at $182.61
174K
2.5% of stake
Jan 2610b5-1 plan
Michael Feld
EVP, CRO & Pres. Life Sciences · sold 75 at $202.73
15K
0.5% of stake
Jan 1510b5-1 plan
Michael David Garrison
EVP & Pres Med.Essntl&BioPharm · sold 1,610 at avg $207.46
334K
12% of stake
Dec 26, 202510b5-1 plan
Michael Feld
EVP, CRO & Pres. Life Sciences · sold 74 at $196.08
15K
0.4% of stake
Dec 17, 202510b5-1 plan
Michael David Garrison
EVP & Pres Med.Essntl&BioPharm · sold 629 at $196.03
123K
4.6% of stake
Dec 1, 202510b5-1 plan
Michael Feld
EVP, CRO & Pres. Life Sciences · sold 75 at $193.36
15K
0.5% of stake
Nov 7, 2025No plan
Bertram L Scott
Director · sold 217 at $176.58
38K
0.6% of stake
Oct 27, 202510b5-1 plan
Michael Feld
EVP & President, Life Sciences · sold 57 at $186.01
11K
0.7% of stake
Sep 26, 202510b5-1 plan
Michael Feld
EVP & President, Life Sciences · sold 58 at $181.03
10K
0.7% of stake
Sep 10, 2025No plan
Claire Fraser
Director · sold 917 at $187.50
172K
4.0% of stake
Aug 22, 202510b5-1 plan
Michael Feld
EVP & President, Life Sciences · sold 57 at $197.99
11K
0.7% of stake
Aug 11, 2025
Gregory Hayes
Director · bought 5,250 at $191.57
$1.01M
660% of stake
Aug 8, 2025No plan
Claire Fraser
Director · sold 863 at $192.30
166K
3.6% of stake
Jul 18, 202510b5-1 plan
Michael David Garrison
EVP & President, Medical · sold 1,185 at avg $180.29
214K
20% of stake
Jun 2, 202510b5-1 plan
David Shan
EVP and Chief ISC Officer · sold 1,166 at $171.19
200K
20% of stake
Apr 9, 202510b5-1 plan
Michael David Garrison
EVP & President, Medical · sold 479 at $197.28
94K
8.9% of stake
Mar 18, 202510b5-1 plan
Richard Byrd
EVP & President Interventional · sold 459 at $230.00
106K
6.2% of stake
Mar 12, 202510b5-1 plan
Richard Byrd
EVP & President Interventional · sold 1,940 at $224.91
436K
21% of stake
Feb 12, 2025No plan
Bertram L Scott
Director · sold 700 at $227.99
160K
1.9% of stake
Feb 10, 2025
Jeffrey William Henderson
Director · bought 1,500 at $233.62
350K
23% of stake
Jan 21, 202510b5-1 plan
David Shan
EVP and Chief ISC Officer · sold 500 at $240.00
120K
8.0% of stake
Jan 21, 202510b5-1 plan
Shana Carol Neal
EVP and Chief People Officer · sold 787 at $240.00
189K
4.9% of stake
Jan 17, 202510b5-1 plan
Michael David Garrison
EVP & President, Medical · sold 597 at $236.51
141K
9.7% of stake
Jan 7, 202510b5-1 plan
Shana Carol Neal
EVP and Chief People Officer · sold 788 at $235.00
185K
4.6% of stake
Dec 19, 202410b5-1 plan
Michael David Garrison
EVP & President, Medical · sold 2,838 at $223.33
634K
32% of stake
Dec 6, 2024 – Dec 9, 202410b5-1 plan
Roland Goette
EVP and President, EMEA · sold 5,121 at avg $220.76
$1.13M
25% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BDX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with BDX

CompareIntrinsic value

BSXBoston Scientific Corporation

$41.97-1.69%77

MMM3M Company

$174.34-1.70%46

SYKStryker Corporation

$291.86-6.38%69

MDLNMedline Inc.

$32.12+0.37%34

BAXBaxter International Inc.

$23.00-2.13%32

SOLVSolventum Corporation

$81.33-2.67%39

RMDResMed Inc.

$229.94-9.05%91

DXCMDexCom, Inc.

$82.32+2.99%88

Held by ETFs

BDX is in 296 US ETFs. The largest of them, with BDX's weight in each:

Spot a number that looks wrong? Check it in BDX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BDX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.